Home » Regions » Global News » Orexo, AstraZeneca enter research agreement for respiratory disease program

Orexo, AstraZeneca enter research agreement for respiratory disease program

Wednesday, January 30, 2013

Orexo, emerging specialty pharmaceutical company based in Sweden, has entered into an agreement with AstraZeneca regarding OX-CLI, a preclinical program for a potential novel treatment of respiratory diseases.

Orexo has granted AstraZeneca rights to conduct further preclinical research and evaluation of compounds in Orexo’s OX-CLI program. AstraZeneca also has an option to acquire the compounds pertaining to the program subject to a full asset transfer agreement being executed by the parties, under which Orexo will receive development milestones and royalties on future revenues.

“Our OX-CLI program is a promising R&D project, which has potential to improve the treatment of respiratory diseases for millions of patients. AstraZeneca, a leading global company within the inflammatory and respiratory area, is the optimal partner for OX-CLI and we look forward to see the project advancing,” said CEO Anders Lundström.

Related Posts